Yael F Shull, PA
Physician Assistant · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Yael F Shull’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence C52273 · Cancelled
Licence status: Cancelled · since 2006 · Saba University School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$40,115
Medicare paid this office $40,115 for 206 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 128 | $27,166 | $109 |
| Return visit (30+ min) | 67 | $6,113 | $74 |
| Telephone medical discussion with physician, 21-30 minutes | 32 | $4,203 | $89 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 48 | $698 | $13 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $549 | $24 |
Who their Medicare patients are
206 Original Medicare patients in 2024. Average age 76 · Women 59% · Also on Medicaid 12% · Health risk score 2.24. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 75% · Cancer 62% · Diabetes 37% · Chronic kidney disease 32% · Coronary heart disease 28% · Atrial fibrillation 27% · Heart failure 20% · Depression 15% · COPD 14% · Dementia 10% · Stroke 9%.
The office billed $165,706, Medicare allowed $56,160 and paid $40,115; for 468 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 206 | 468 | 76 | 2.24 | $165,706 | $40,115 |
| 2023 | 247 | 531 | 76 | 2.00 | $209,001 | $46,114 |
| 2022 | 277 | 545 | 76 | 1.94 | $231,213 | $48,333 |
| 2021 | 277 | 593 | 75 | 2.00 | $259,379 | $57,734 |
| 2020 | 283 | 630 | 75 | 2.09 | $171,721 | $45,525 |
| 2019 | 315 | 783 | 76 | 2.18 | $94,060 | $54,172 |
| 2018 | 259 | 18,295 | 76 | 2.38 | $1,472,476 | $395,787 |
| 2017 | 239 | 24,180 | 75 | 2.18 | $1,705,556 | $374,426 |
| 2016 | 52 | 3,012 | 74 | 2.19 | $173,369 | $34,895 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 130 | $28,987 | $106 |
| Return visit (30+ min) | 123 | $11,229 | $69 |
| Telephone medical discussion with physician, 21-30 minutes | 49 | $4,725 | $66 |
2022: 4 services
| Long return visit (40+ min) | 127 | $26,494 | $108 |
| Return visit (30+ min) | 142 | $13,634 | $70 |
| Telephone medical discussion with physician, 21-30 minutes | 58 | $4,796 | $63 |
| New patient visit (60+ min) | 24 | $3,219 | $134 |
2021: 4 services
| Long return visit (40+ min) | 117 | $29,958 | $116 |
| Return visit (30+ min) | 137 | $15,148 | $75 |
| Telephone medical discussion with physician, 21-30 minutes | 68 | $6,567 | $74 |
| New patient visit (60+ min) | 41 | $5,982 | $146 |
2020: 4 services
| Return visit (30+ min) | 196 | $24,464 | $60 |
| Long return visit (40+ min) | 78 | $9,854 | $87 |
| New patient visit (60+ min) | 74 | $9,348 | $126 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $1,337 | $64 |
2019: 3 services
| Return visit (30+ min) | 210 | $31,368 | $57 |
| New patient visit (60+ min) | 97 | $12,292 | $127 |
| Long return visit (40+ min) | 91 | $10,097 | $83 |
2018: 11 services
| Return visit (30+ min) | 182 | $38,819 | $68 |
| Long return visit (40+ min) | 92 | $11,669 | $96 |
| Administration of chemotherapy into vein, 1 hour or less | 32 | $7,361 | $127 |
| New patient visit (60+ min) | 41 | $5,191 | $127 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 87 | $1,645 | $9 |
| Short return visit (20+ min) | 23 | $1,453 | $52 |
| Injection of additional new drug or substance into vein | 21 | $1,035 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 13 | $735 | $27 |
| Injection of drug or substance under skin or into muscle | 25 | $648 | $17 |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $26 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | $12 | None |
2017: 17 services
| Return visit (30+ min) | 167 | $28,913 | $84 |
| Injection, denosumab, 1 mg | 12 | $23,870 | None |
| Long return visit (40+ min) | 112 | $16,083 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 44 | $7,398 | $119 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $6,983 | None |
| Injection, palonosetron hcl, 25 mcg | 15 | $3,267 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 127 | $2,748 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 34 | $1,900 | $26 |
| Injection of drug or substance under skin or into muscle | 42 | $1,141 | $20 |
| Injection of additional new drug or substance into vein | 27 | $975 | $19 |
| Administration of additional new drug or substance into vein, 1 hour or less | 12 | $744 | $57 |
| Short return visit (20+ min) | 13 | $719 | $51 |
| Administration of chemotherapy into vein, each additional hour | 12 | $557 | $24 |
| Insertion of needle into vein for collection of blood sample | 13 | $44 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 32 | $35 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $17 | None |
| Not otherwise classified, antineoplastic drugs | 14 | $10 | None |
2016: 4 services
| Return visit (30+ min) | 35 | $3,423 | $83 |
| Short return visit (20+ min) | 13 | $875 | $58 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 29 | $405 | $10 |
| Insertion of needle into vein for collection of blood sample | 28 | $112 | $3 |
Drugs they prescribed that Part D paid
$2,353,325
Pharmacies billed $2,353,325 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (12 of 739) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
584 generic and 155 brand-name prescriptions · $2,353,325 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 20 | $329,150 | $16,458 |
| Lenalidomide | 18 | $277,042 | $15,391 |
| Imbruvica | 16 | $246,244 | $15,390 |
| Inlyta | 11 | $227,733 | $20,703 |
| Xtandi | 14 | $227,673 | $16,262 |
See all 20 drugs
| Tagrisso | 20 | $329,150 | $16,458 |
| Lenalidomide | 18 | $277,042 | $15,391 |
| Imbruvica | 16 | $246,244 | $15,390 |
| Inlyta | 11 | $227,733 | $20,703 |
| Xtandi | 14 | $227,673 | $16,262 |
| Ibrance | 11 | $181,057 | $16,460 |
| Venclexta | 11 | $167,783 | $15,253 |
| Imatinib Mesylate | 28 | $45,101 | $1,611 |
| Abiraterone Acetate | 34 | $31,003 | $912 |
| Eliquis | 27 | $25,850 | $957 |
| Anastrozole | 135 | $3,166 | $23 |
| Ondansetron | 40 | $1,685 | $42 |
| Letrozole | 25 | $713 | $29 |
| Gabapentin | 24 | $537 | $22 |
| Hydroxyurea | 17 | $424 | $25 |
| Acyclovir | 16 | $337 | $21 |
| Prochlorperazine Maleate | 32 | $302 | $9 |
| Dexamethasone | 19 | $293 | $15 |
| Prednisone | 31 | $148 | $5 |
| Ibuprofen | 14 | $81 | $6 |
Year by year
| 2024 | 739 | 224 | 2% (12) | 21% | $2,353,325 |
| 2023 | 806 | 213 | 2% (14) | None | $2,892,536 |
| 2022 | 793 | 227 | 3% (23) | None | $2,262,726 |
| 2021 | 1,019 | 279 | 4% (39) | 24% | $2,138,099 |
| 2020 | 1,658 | 403 | 4% (59) | 23% | $2,967,995 |
| 2019 | 1,798 | 402 | 4% (72) | 26% | $3,254,239 |
| 2018 | 1,276 | 280 | 7% (94) | 21% | $1,994,261 |
| 2017 | 1,209 | 249 | 8% (93) | 18% | $1,215,006 |
| 2016 | 1,139 | 234 | 8% (90) | 18% | $728,619 |
| 2015 | 574 | 148 | 12% (67) | 21% | $552,311 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Imbruvica | 24 | $390,273 | $16,261 |
| Revlimid | 15 | $382,853 | $25,524 |
| Xtandi | 27 | $351,135 | $13,005 |
| Tagrisso | 18 | $302,200 | $16,789 |
| Venclexta | 14 | $220,398 | $15,743 |
| Ibrance | 13 | $195,241 | $15,019 |
| Imatinib Mesylate | 33 | $91,562 | $2,775 |
| Abiraterone Acetate | 37 | $22,801 | $616 |
| Eliquis | 21 | $18,031 | $859 |
| Xarelto | 15 | $16,874 | $1,125 |
| Anastrozole | 131 | $4,185 | $32 |
| Hydroxyurea | 18 | $800 | $44 |
| Acyclovir | 19 | $688 | $36 |
| Prednisone | 43 | $642 | $15 |
| Ondansetron | 30 | $362 | $12 |
| Letrozole | 12 | $316 | $26 |
| Prochlorperazine Maleate | 25 | $277 | $11 |
| Lidocaine-Prilocaine | 12 | $213 | $18 |
| Gabapentin | 15 | $179 | $12 |
| Ibuprofen | 19 | $92 | $5 |
| Lorazepam | 15 | $57 | $4 |
2022: 22 drugs
| Revlimid | 17 | $402,917 | $23,701 |
| Imbruvica | 19 | $285,937 | $15,049 |
| Venclexta | 18 | $258,052 | $14,336 |
| Xtandi | 14 | $185,479 | $13,249 |
| Xarelto | 27 | $29,427 | $1,090 |
| Eliquis | 28 | $25,628 | $915 |
| Abiraterone Acetate | 29 | $16,014 | $552 |
| Anastrozole | 112 | $3,212 | $29 |
| Hydroxyurea | 20 | $2,133 | $107 |
| Acyclovir | 25 | $757 | $30 |
| Dexamethasone | 21 | $587 | $28 |
| Ondansetron | 41 | $558 | $14 |
| Gabapentin | 24 | $517 | $22 |
| Prednisone | 27 | $454 | $17 |
| Potassium Chloride | 14 | $376 | $27 |
| Letrozole | 21 | $339 | $16 |
| Hydrocodone-Acetaminophen | 12 | $279 | $23 |
| Prochlorperazine Maleate | 20 | $278 | $14 |
| Loperamide | 11 | $277 | $25 |
| Lidocaine-Prilocaine | 13 | $269 | $21 |
| Alendronate | 16 | $151 | $9 |
| Ibuprofen | 15 | $32 | $2 |
2021: 24 drugs
| Cabometyx | 14 | $329,921 | $23,566 |
| Imbruvica | 23 | $312,674 | $13,595 |
| Tagrisso | 19 | $301,179 | $15,852 |
| Xtandi | 21 | $263,264 | $12,536 |
| Zejula | 11 | $203,146 | $18,468 |
| Eliquis | 43 | $32,883 | $765 |
| Abiraterone Acetate | 22 | $27,425 | $1,247 |
| Xarelto | 21 | $19,294 | $919 |
| Creon | 17 | $15,646 | $920 |
| Exemestane | 28 | $9,095 | $325 |
| Anastrozole | 215 | $7,088 | $33 |
| Tamoxifen Citrate | 34 | $2,142 | $63 |
| Hydroxyurea | 24 | $1,824 | $76 |
| Letrozole | 42 | $1,505 | $36 |
| Dexamethasone | 35 | $938 | $27 |
| Gabapentin | 34 | $697 | $21 |
| Ondansetron | 45 | $646 | $14 |
| Potassium Chloride | 11 | $595 | $54 |
| Hydrocodone-Acetaminophen | 30 | $549 | $18 |
| Acyclovir | 20 | $376 | $19 |
| Prochlorperazine Maleate | 34 | $370 | $11 |
| Alendronate | 16 | $224 | $14 |
| Prednisone | 18 | $217 | $12 |
| Levothyroxine | 11 | $202 | $18 |
2020: 29 drugs
| Imbruvica | 41 | $538,574 | $13,136 |
| Ibrance | 36 | $466,936 | $12,970 |
| Xtandi | 33 | $345,842 | $10,480 |
| Zytiga | 19 | $211,924 | $11,154 |
| Jakafi | 11 | $122,367 | $11,124 |
| Imatinib Mesylate | 21 | $66,578 | $3,170 |
| Eliquis | 84 | $49,225 | $586 |
| Abiraterone Acetate | 26 | $46,294 | $1,781 |
| Exemestane | 38 | $18,135 | $477 |
| Xarelto | 16 | $17,586 | $1,099 |
| Anastrozole | 357 | $11,742 | $33 |
| Letrozole | 78 | $3,139 | $40 |
| Tamoxifen Citrate | 42 | $3,056 | $73 |
| Hydroxyurea | 23 | $2,112 | $92 |
| Ondansetron | 99 | $1,550 | $16 |
| Hydrocodone-Acetaminophen | 45 | $1,086 | $24 |
| Acyclovir | 41 | $1,010 | $25 |
| Gabapentin | 53 | $999 | $19 |
| Potassium Chloride | 26 | $965 | $37 |
| Dexamethasone | 40 | $872 | $22 |
| Prochlorperazine Maleate | 45 | $702 | $16 |
| Prednisone | 56 | $633 | $11 |
| Alendronate | 48 | $489 | $10 |
| Levothyroxine | 27 | $388 | $14 |
| Allopurinol | 19 | $239 | $13 |
| Duloxetine | 13 | $233 | $18 |
| Cyclobenzaprine | 12 | $175 | $15 |
| Zolpidem | 24 | $108 | $5 |
| Omeprazole | 11 | $101 | $9 |
2019: 35 drugs
| Ibrance | 37 | $462,168 | $12,491 |
| Zytiga | 41 | $457,668 | $11,163 |
| Xtandi | 37 | $357,026 | $9,649 |
| Jakafi | 22 | $311,292 | $14,150 |
| Imbruvica | 18 | $220,326 | $12,240 |
| Promacta | 13 | $117,538 | $9,041 |
| Abiraterone Acetate | 12 | $75,070 | $6,256 |
| Eliquis | 106 | $65,753 | $620 |
| Exemestane | 30 | $16,108 | $537 |
| Xarelto | 13 | $15,978 | $1,229 |
| Anastrozole | 285 | $8,937 | $31 |
| Tamoxifen Citrate | 69 | $4,799 | $70 |
| Letrozole | 124 | $4,632 | $37 |
| Hydroxyurea | 81 | $4,589 | $57 |
| Ondansetron | 81 | $1,129 | $14 |
| Hydrocodone-Acetaminophen | 43 | $1,086 | $25 |
| Acyclovir | 44 | $911 | $21 |
| Dexamethasone | 41 | $845 | $21 |
| Prednisone | 64 | $750 | $12 |
| Gabapentin | 60 | $729 | $12 |
| Alendronate | 44 | $628 | $14 |
| Prochlorperazine Maleate | 49 | $616 | $13 |
| Bicalutamide | 18 | $608 | $34 |
| Potassium Chloride | 11 | $498 | $45 |
| Venlafaxine Hcl Er | 15 | $469 | $31 |
| Lidocaine-Prilocaine | 22 | $460 | $21 |
| Levothyroxine | 27 | $452 | $17 |
| Allopurinol | 35 | $413 | $12 |
| Lidocaine Hcl Viscous | 14 | $400 | $29 |
| Droxia | 12 | $286 | $24 |
| Lorazepam | 25 | $165 | $7 |
| Zolpidem | 15 | $132 | $9 |
| Ondansetron Odt | 11 | $126 | $11 |
| Ibuprofen | 13 | $105 | $8 |
| Sulfamethoxazole-Trimethoprim | 13 | $75 | $6 |
2018: 32 drugs
| Xtandi | 26 | $298,133 | $11,467 |
| Zytiga | 26 | $277,070 | $10,657 |
| Ibrance | 23 | $267,386 | $11,625 |
| Promacta | 28 | $233,407 | $8,336 |
| Jakafi | 14 | $180,117 | $12,865 |
| Revlimid | 12 | $171,748 | $14,312 |
| Eliquis | 49 | $26,842 | $548 |
| Exemestane | 13 | $9,998 | $769 |
| Anastrozole | 153 | $3,856 | $25 |
| Enoxaparin | 12 | $3,824 | $319 |
| Tamoxifen Citrate | 48 | $3,564 | $74 |
| Hydrocodone-Acetaminophen | 57 | $1,490 | $26 |
| Hydroxyurea | 37 | $1,486 | $40 |
| Letrozole | 45 | $1,383 | $31 |
| Dexamethasone | 43 | $1,106 | $26 |
| Ondansetron | 102 | $1,031 | $10 |
| Oxycodone-Acetaminophen | 16 | $732 | $46 |
| Gabapentin | 49 | $525 | $11 |
| Prochlorperazine Maleate | 79 | $508 | $6 |
| Prednisone | 39 | $444 | $11 |
| Acyclovir | 17 | $400 | $24 |
| Lidocaine-Prilocaine | 17 | $390 | $23 |
| Allopurinol | 24 | $278 | $12 |
| Hydromorphone | 16 | $266 | $17 |
| Warfarin | 12 | $202 | $17 |
| Temazepam | 11 | $201 | $18 |
| Alendronate | 13 | $190 | $15 |
| Zolpidem | 22 | $126 | $6 |
| Lorazepam | 23 | $126 | $5 |
| Klor-Con M20 | 12 | $102 | $9 |
| Amlodipine Besylate | 12 | $64 | $5 |
| Omeprazole | 13 | $29 | $2 |
2017: 32 drugs
| Ibrance | 26 | $288,047 | $11,079 |
| Promacta | 23 | $172,080 | $7,482 |
| Xtandi | 15 | $152,081 | $10,139 |
| Zytiga | 13 | $130,495 | $10,038 |
| Procrit | 16 | $67,046 | $4,190 |
| Eliquis | 21 | $10,154 | $484 |
| Gleostine | 18 | $7,484 | $416 |
| Oxycontin | 14 | $4,162 | $297 |
| Tamoxifen Citrate | 50 | $3,157 | $63 |
| Anastrozole | 112 | $2,428 | $22 |
| Oxycodone-Acetaminophen | 34 | $1,274 | $37 |
| Letrozole | 46 | $1,025 | $22 |
| Dexamethasone | 54 | $834 | $15 |
| Hydroxyurea | 27 | $791 | $29 |
| Lidocaine-Prilocaine | 28 | $784 | $28 |
| Ondansetron | 119 | $750 | $6 |
| Prochlorperazine Maleate | 120 | $713 | $6 |
| Gabapentin | 46 | $693 | $15 |
| Acyclovir | 23 | $655 | $28 |
| Hydrocodone-Acetaminophen | 37 | $635 | $17 |
| Warfarin | 12 | $509 | $42 |
| Valacyclovir | 11 | $373 | $34 |
| Temazepam | 13 | $213 | $16 |
| Prednisone | 26 | $204 | $8 |
| Allopurinol | 17 | $198 | $12 |
| Lisinopril | 15 | $167 | $11 |
| Levofloxacin | 11 | $111 | $10 |
| Alendronate | 19 | $111 | $6 |
| Ondansetron Odt | 18 | $88 | $5 |
| Zolpidem | 15 | $69 | $5 |
| Sulfamethoxazole-Trimethoprim | 12 | $56 | $5 |
| Lorazepam | 11 | $35 | $3 |
2016: 27 drugs
| Xtandi | 21 | $189,327 | $9,016 |
| Zytiga | 20 | $171,457 | $8,573 |
| Promacta | 15 | $101,593 | $6,773 |
| Procrit | 11 | $40,449 | $3,677 |
| Xarelto | 28 | $10,150 | $363 |
| Oxycontin | 13 | $3,608 | $278 |
| Anastrozole | 142 | $2,506 | $18 |
| Oxycodone-Acetaminophen | 31 | $1,621 | $52 |
| Tamoxifen Citrate | 29 | $1,317 | $45 |
| Letrozole | 32 | $1,225 | $38 |
| Lidocaine-Prilocaine | 42 | $1,139 | $27 |
| Hydrocodone-Acetaminophen | 34 | $923 | $27 |
| Hydroxyurea | 46 | $861 | $19 |
| Ondansetron | 108 | $807 | $7 |
| Bicalutamide | 18 | $756 | $42 |
| Mirtazapine | 21 | $701 | $33 |
| Valacyclovir | 16 | $520 | $33 |
| Dexamethasone | 50 | $454 | $9 |
| Prochlorperazine Maleate | 69 | $437 | $6 |
| Gabapentin | 45 | $417 | $9 |
| Acyclovir | 16 | $319 | $20 |
| Allopurinol | 19 | $257 | $14 |
| Prednisone | 29 | $243 | $8 |
| Temazepam | 12 | $197 | $16 |
| Alendronate | 19 | $158 | $8 |
| Lisinopril | 20 | $123 | $6 |
| Amlodipine Besylate | 21 | $86 | $4 |
2015: 15 drugs
| Xtandi | 13 | $115,986 | $8,922 |
| Zytiga | 14 | $112,835 | $8,060 |
| Xarelto | 13 | $5,765 | $443 |
| Oxycontin | 13 | $3,235 | $249 |
| Oxycodone-Acetaminophen | 32 | $1,627 | $51 |
| Lidocaine-Prilocaine | 26 | $976 | $38 |
| Ondansetron | 77 | $713 | $9 |
| Tamoxifen Citrate | 13 | $676 | $52 |
| Anastrozole | 40 | $601 | $15 |
| Hydroxyurea | 22 | $485 | $22 |
| Acyclovir | 15 | $290 | $19 |
| Prochlorperazine Maleate | 52 | $275 | $5 |
| Dexamethasone | 27 | $215 | $8 |
| Prednisone | 14 | $99 | $7 |
| Pantoprazole | 11 | $72 | $7 |
Money from drug and device companies
$31 in 2025
| 2025 | 1 | 1 | None | $31 |
| 2024 | 1 | 2 | None | $117 |
| 2023 | 1 | 3 | None | $149 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Caris MPI | Mi Cancer Seek | $31 | 1 payment
|
See the published payment
| Caris MPI | Meals · 2025-06-05 | Mi Cancer Seek | $31 |
See earlier years (2024, 2023)
2024: $117
| GlaxoSmithKline | Ojjaara | $117 | 2 payments
|
2023: $149
| GlaxoSmithKline | Ojjaara | $149 | 3 payments
|
Professional record
- NPI
- 1194115907
- Licence
- CA 52273California C52273: Cancelled
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, medical (363AM0700X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2015-02-01
- NPI last updated
- 2025-12-23
- NPI record certified
- 2025-12-23
This is when the NPI record was last certified, not a medical board exam.